SOTALOL

USDailyMed:Sotalol AU:C C07AA07(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-only (RS)-N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide 3930-20-9Y 5253 7297 DB00489Y 5063Y A6D97U294I D08525Y ChEMBL471Y DTXSID0023589 Interactive image O=S(=O)(Nc1ccc(cc1)C(O)CNC(C)C)C InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3YKey:ZBMZVLHSJCTVON-UHFFFAOYSA-NY Sotalol, sold under the brand nameBetapaceamong others, is a medication used to treat and preventabnormal heart rhythms.Evidence does not support a decreased risk of death with long term use.It is takenby mouthor given byinjection into a vein. Common side effects include aslow heart rate,chest pain,low blood pressure, feeling tired, dizziness, shortness of breath, problems seeing, vomiting, andswelling.Other serious side effects may includeQT prolongation,heart failure, orbronchospasm.Sotalol is a non-selectiveβ-adrenergic receptor blockerwhich has bothclass IIandclass III antiarrhythmicproperties. Sotalol was first described in 1964 and came into medical use in 1974.It is available as ageneric medication.In 2020, it was the 296th most commonly prescribed medication in the United States, with more than 1million prescriptions.